Ming  Lu, M.D., Ph.D. Staff  Research Associate IV
INSTITUTION  AND LOCATION	DEGREE (if  applicable)		YEAR(s)	FIELD  OF STUDY
Harbin  Medical University, China	MD		1989-1996	Clinical  Medicine
Purdue  University, West Lafayette, Indiana	PhD		1997-2000	Cancer  Biology
Purdue  University, West Lafayette, Indiana	Postdoc.		2001-2002	Cancer  Biology
David  Geffen School of Medicine at UCLA	Postdoc.		2003-2005	Molecular  Biology and Cancer Biology

 

 

Please refer to the application instructions in order to complete sections A, B, and C of the Biographical Sketch.

 

A.     Positions and Honors. List in chronological order previous positions, concluding with your present position. List any honors. Include present membership on any Federal Government public advisory committee.

Honors and Awards:

2006                           GenNext Technologies Inc. Young Investigator Scholarship;

2003                            American Heart Association (AHA) New Investigator Award;

1997-2000                   Graduate Fellowship Award, Purdue University;

1999                            H. Ismail Interdisciplinary Program Doctor Research Travel Award;

1989-1997                   University Foundation Scholarship, Harbin Medical University;

1993-1997                   Honor Student, Harbin Medical University;

1993-1997                   Dean’s List, Harbin Medical University;

1993                            National Outstanding Student.

 

Research Experiences:

2010-present:             

Position Title:               Staff Research Associate IV

Organization:               David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

2006-2010:

Position Title:               Assistant Researcher II

Organization:               David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

2002-2005:

Position Title:               Postdoctoral Research Fellow

Organization:               David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

1997-2002:

Position Title:               Ph.D. Student and Postdoctoral Research Fellow

Organization:               Purdue University, West Lafayette, IN, USA

1989-1997:

Position Title:               Medical School Student & Research Assistant.

Organization:               Harbin Medical University, Harbin, China

 

Selected peer-reviewed publications (in chronological order):

1.     Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Res Treat. 2013 Oct;141(3):397-408. doi: 10.1007/s10549-013-2702-z. Epub 2013 Oct 5.

2.    He J, Whelan SA, Lu M, Shen D, Chung DU, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response.

Int J Proteomics. 2011;2011:896476. doi: 10.1155/2011/896476. Epub 2011 Oct 24.

3.    Lu M, Whitelegge JP, Whelan SA, He J, Saxton RE, Faull KF and Chang HR. Hydrophobic Fractionation Enhances Novel Protein Detection by Mass Spectrometry in Triple Negative Breast Cancer. J. Proteomics & Bioinformatics. 3.2: 029-038. 2010.

4.    Lu M,Whelan SA, He J, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Hydrophobic Proteome Of Triple Negative And Hormone-Receptor-Positive-Her2-Negative Breast Cancer Study With Mass Spectrometer. In press. Clinical Proteomics. 2010.

5.    He J, Whelan SA, Lu M, Shen D, Chung DU, Saxton RE, Faull KF, Whitelegge JP, and Chang HR. Mass spectrometry identified protein bio-signatures in classifying breast cancer and predicting responses to chemotherapy. Submitted to Molecular and Cellular Proteomics (MCP). 2010.

6.    Whelan SA, He J, Lu M, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid. Submitted. 2010.

7.    Whelan SA, Lu M, He J, Yan W, Saxton RE, Faull KF, Whitelegge JP, Chang HR. Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers. J Proteome Res. 8:4151-60. 2009.

8.    Norris AJ, Sartippour MR, Lu M, Park T, Rao J, Jackson MI, Jfukuto JM, Brooks MN. Nitroxyl inhibits breast tumor growth and angiogenesis. Cancer Res. 122: 1905-1910. 2008.

9.    Lu M, Faull KF, Whitelegge JP, Saxton RK, Shen D, Chang HR. Mass Spectrometry for Cancer Biomarker Discovery. Biomarker Insights. 2: 347-360. 2007.

10.   Lu M, Sartippour MR, Zhang L, Norris AJ, and Brooks MN. Targeted inhibition of EG-1 blocks breast tumor growth. Cancer Biology & Therapy. 6: 936-941. 2007.

11.   He J, Gornbein J, Shen D, Lu M, Rovai-Chaves LE, Shau H, Katz J, Whitelegge JP, Faull KF, Chang HR. Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry. Int J Oncol. 30:145-154, 2007.

12.   Lu M, Zhang L, Sartippour MR, Norris AJ and Brooks MN. EG-1 interacts with c-Src and activates its signaling pathway. Int J Oncol. 29:1013-8. 2006.

13.   Sartippour MR, Pietras R, Marquez-Garban DC, Chen H, Heber D, Henning SM, Sartippour J, Zhang L, Lu M, Weinberg O, Rao J, Brooks MN. The combination of green tea and tamoxifen is effective against breast cancer. Carcinogenesis. 27:2424-2433, 2006.

14.   Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, Craig BA, Lu M, Wu L, Zheng R, Stewart J, Knapp DW. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol. Cancer Ther., 5:329-36, 2006.

15.   Lu M, Zhang L, Maul RS, Sartippour MR, Norris A, Whitelegge J, Rao J, Brooks MN. The novel gene EG-1 stimulates cellular proliferation. Cancer Res. 65: 6159-6166, 2005.

16.   Sartippour MR, Seeram NP, Heber D, Hardy M, Norris A, Lu Q, Zhang L, Lu M, Rao J, Brooks MN. Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int. J. Oncol. 26(1):121-127, 2005.

17.   Sartippour MR, Zhang L, Lu M, Wang H and Brooks MN. Nipple fluid basic fibroblast growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev. 14(12):2995-2998, 2005.

18.   Zhang J, Ping P, Wang G, Lu M, Pantaleon D, Tang XL, Bolli R, Vondriska TM. Bmx, a member of the Tec family of nonreceptor tyrosine kinases, is a novel participant in pharmacological cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 287(5):H2364-2366. 2004.

19.   Lu M, Miller KD, Gokem-Polar Y, Jeng MH, Kinch MS. EphA2 Overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 63: 3425-3429, 2003.

20.   Belury MA, Moya-Camarena SY, Lu M, Shi L, Leesnitzer LA, Blanchard SG.  Conjugated linoleic acid is an activator but not a high affinity ligand for peroxisome proliferator-activated receptor–gamma. Nutrition Res. 22: 817-824, 2002.

21.   Lu M. The new method of selection clones by differential display (DD) before RNA study. Foreign Medical Sciences 21: 44-45, 1998.

22.   Fu S, Li Y, Lu M, Li P, et al. The latest molecular biology and biotechnology laboratory methods. (Book chapter) Heilongjiang Sci-tech Press. 1997.

23.   Lu M, Qiao X, Zhao J. Analysis of population mortality rate incurred by injury and poisoning in Zhaodong of Year 1988-1994. J. Harbin Med. Univ. 29(6): 126-127, 1995.

24.   Qiao X, Lu M, Zhao J. Dynamic analysis of population PYLL due to cardiovascular diseases in Zhaodong county of year 1988-1994. J. Harbin Med. Univ. 29(6): 114-116, 1995.

25.   Lu M, Xing S. Humoral immunological alternations in chronic hepatitis B patients. J. of Harbin Med. Univ. 27(6): 42-43, 1993.